title: Characterization of two novel sublines established from a human megakaryoblastic leukemia cell line transfected with p210(BCR-ABL).
abstract: Disease progression in chronic myelogenous leukemia (CML) is usually accompanied by chromosomal abnormalities such as an additional Ph chromosome, trisomies of chromosome 8 or 19, or i(17) in addition to the standard translocation t(9;22) (q34;q11). However, detailed studies of the various steps involved during this evolution are difficult to perform, thereby making the study of cell lines that contain the transposed genes BCR-ABL, especially those of human origin, an important focus. In this analysis we investigated the human megakaryoblastic cell line MO7e and its subline transfected with BCR-ABL, MO7e/p210. Initial studies demonstrated that the phenotype of the MO7e line was consistent with a megakaryocytic lineage as originally described and was growth factor dependent in liquid culture. The MO7e/p210 subline, however, was growth factor independent and could be further separated into two distinct sublines based on expression of glycophorin A using the monoclonal antibody R10. The subline R10 negative (R10-) was similar to the parent line MO7e but R10 positive (R10+) cells had a distinct erythroid phenotype. In addition, the R10- and R10+ sublines demonstrated strikingly different colony morphology when cultured in semisolid medium. Furthermore, R10+ cells had additional chromosomal abnormalities not detected in the R10- population. These results demonstrate that the insertion of the BCR-ABL in this human leukemia cell line resulted in two distinct subpopulations of cells, each now growth factor independent, but one with a phenotype and karyotype identical to the parent cell line and the other with a different phenotype and additional chromosomal abnormalities. These two subpopulations derived from the MO7e/p210 transfected cell line may prove useful in further understanding the multistep events that occur in the progression of this disease.
authors.affiliation: Department of Medicine, The Laboratory of Hematopoietic Cell Kinetics, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.
authors.forename: E
authors.initials: E
authors.lastname: Berman
authors.forename: S
authors.initials: S
authors.lastname: Jhanwar
authors.forename: M
authors.initials: M
authors.lastname: McBride
authors.forename: A
authors.initials: A
authors.lastname: Strife
authors.forename: D
authors.initials: D
authors.lastname: Wisniewski
authors.forename: C
authors.initials: C
authors.lastname: Lambek
authors.forename: B
authors.initials: B
authors.lastname: Clarkson
mesh_terms: D002869:Chromosome Aberrations; D016044:Fusion Proteins, bcr-abl / Q000235:genetics / Q000502:physiology*; D006801:Humans; D016130:Immunophenotyping; D007947:Leukemia, Megakaryoblastic, Acute / Q000235:genetics / Q000276:immunology / Q000473:pathology*; D012150:Polymorphism, Restriction Fragment Length; D014162:Transfection; D014407:Tumor Cells, Cultured
chemical_list: D016044:Fusion Proteins, bcr-abl